Close Menu

NEW YORK – DiaSorin announced on Thursday it has received approval from the US Food and Drug Administration for six hepatitis B serology assays. The Saluggia, Italy-based firm said the tests now complete its hepatitis menu offering in the US market.

The six tests comprise an HBV panel. It runs on the firm's Liaison XL chemiluminescent immunoassay system which has a global installed base of 5,000 instruments, DiaSorin noted in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.